Masoud Rashidi, PharmD discusses LDN and Pain (LDN, low dose naltrexone) from LDN Research Trust on Vimeo.

Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin

eNeuro
126 June 2021
https://pubmed.ncbi.nlm.nih.gov/34031099/

Integrated Review of the Assessment of Newborns With Neonatal Abstinence Syndrome

J Obstet Gynecol Neonatal Nurs
08 June 2021
https://pubmed.ncbi.nlm.nih.gov/34116058/

Objective: To critically review and summarize current knowledge regarding the assessment of newborns with neonatal abstinence syndrome (NAS).

Extended-release naltrexone for youth with opioid use disorder

J Subst Abuse Treat
15 April 2021
https://pubmed.ncbi.nlm.nih.gov/34118699/

Background: Few published research studies have examined the effectiveness of extended-release naltrexone (XR-NTX) for the treatment of opioid use disorder (OUD) among adolescents and young adults.

Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review

Pain Physician
July 2021
https://pubmed.ncbi.nlm.nih.gov/34213865/

Background: Complex regional pain syndrome is a rare, neuropathic disorder that affects fewer than 200,000 individuals in the United States annually. Current treatments often focus on pain management and fall short of relieving symptoms of pain and dystonia in patients.

Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice

CNS Neurosci Ther
21 May 2021
https://pubmed.ncbi.nlm.nih.gov/34018697/

Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy

Int Immunopharmacol
11 May 2021
https://pubmed.ncbi.nlm.nih.gov/33989971/

Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients

Hum Psychopharmacol
24 May 2021
https://pubmed.ncbi.nlm.nih.gov/34029405/

Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and Beta-Endorphin

eNeuro
24 May 2021
https://www.eneuro.org/content/early/2021/05/21/ENEURO.0087-21.2021

Addiction Medication Promising for Chronic, Refractory Pain

Medscape Medical News
01 May 2021
https://www.medscape.com/viewarticle/950263

Preliminary data from a retrospective chart review of patients with chronic pain showed those who received LDN experienced significant improvement in both pain and disability.